Kejing Tang
Peking Union Medical College
80 Papers
165 Citations
Kejing Tang is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 14, co-authored 61 publications.
Chat about Author
Papers
[CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
X H Fu,Y. F. Wang,H J Wang,S N Wei,Y X Xu,H Y Xing,Kejing Tang,Zhigang Tian,Qing Rao,J X Wang,Mengzhao Wang +10 more
TL;DR: Targeting or combining an alternative antigen specific CAR-T may be a promising treatment option after losing CD19 expression in relapsed ALL and exploring the resistance mechanism of BiTE immunotherapy is explored.
FHL2 Interacts with Iaspp and Impacts the Biological Functions of Leukemia Cells
Wen-Hsien Lu,Tengteng Yu,Shuang Liu,Saisai Li,Shouyun Li,Jia Liu,Haiyan Xing,Zheng Tian,Kejing Tang,Qing Rao,Jianxiang Wang,Min Wang +11 more
- 02 Dec 2016
TL;DR: The interaction between FHL2 and iASPP in AML was observed for the first time and indicated that FHL 2 might be a novel potential target for AML treatment.
A New Caspase-8 Isoform Caspase-8s Increased Sensitivity to Apoptosis in Jurkat Cells
TL;DR: A novel short isoform of caspase-8 (caspase -8s), which encodes the first (Death Effector Domain) DED and part of the second DED, missing the C-terminal caspases domain is reported, suggesting that casp enzyme-8s may act as a promoter of apoptosis through binding to FADD and is involved in the regulation of apoptotic activity.
Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth
Jiying Wang,Qing Rao,Min Wang,Hui Wei,Haiyan Xing,Hang Liu,Yanzhong Wang,Kejing Tang,Leiwen Peng,Zheng Tian,Jianxiang Wang +10 more
TL;DR: It is concluded that overexpression of Rac1 contributes to the accelerated migration and high proliferation potential of leukemia cells, which could be implicated in leukemia development and progression.
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy
Man-Yu Chen,Xiaoyu Liu,N. Peng,Tingting Zhang,Junli Mou,Huizhen He,Yu Wang,Yingxi Xu,Haiyan Xing,Kejing Tang,Zheng Tian,Qing Rao,Runxia Gu,Shaowei Qiu,Min Wang,Jianxiang Wang +15 more
TL;DR: Both DuAb and EDuAb showed great potential as novel treatments for B-ALL in clinical applications and showed a better promising effect on eliminating tumor cells and extending survival in vivo, which provides new insights for the development of new multi-specific antibodies.